Track Simulations Plus, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Simulations Plus, Inc. SLP Open Simulations Plus, Inc. in new tab

11.99 USD
P/E
65.06
EPS
-3.20
P/B
1.80
ROE
-41.21
Beta
1.22
Target Price
24.67 USD
Simulations Plus, Inc. logo

Simulations Plus, Inc.

🧾 Earnings Recap – Q1 2026

Simulations Plus reported a 3% decline in revenue for Q1 FY2026, reflecting anticipated market conditions, although its Services segment showed a strong 16% growth, contributing positively to overall performance.

  • Total revenue decreased to $18.4 million, driven by a 17% decline in software revenue but offset by a 16% growth in Services revenue.
  • Adjusted EBITDA for the quarter was $3.5 million, with a consistent adjusted EPS of $0.13.
  • The company's average revenue per client was $97,000, with a solid 88% renewal rate.
  • Ending backlog increased by 18% to $20.4 million, indicating a robust pipeline of services projects.
  • Fiscal year 2026 revenue guidance maintained at $79 million to $82 million, projecting minimal growth amid a shifting market landscape.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateApril 9, 2026
P/E65.06
EPS-3.20
Book Value6.31
Price to Book1.80
Debt/Equity0.44
% Insiders17.315%
Growth
Revenue Growth-0.03%
Earnings Growth2.00%
Estimates
Forward P/E10.67
Forward EPS1.07
Target Mean Price24.67

DCF Valuation

Tweak assumptions to recompute fair value for Simulations Plus, Inc. (SLP)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Simulations Plus, Inc. Logo Simulations Plus, Inc. Analysis (SLP)

United States Health Care Official Website Stock

Is Simulations Plus, Inc. a good investment? Simulations Plus, Inc. (SLP) is currently trading at 11.99 USD. Market analysts have a consensus price target of 24.67 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 65.06. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: Simulations Plus, Inc. is expected to release its next earnings report on April 9, 2026. The market consensus estimate for Forward EPS is 1.07.

Investor FAQ

Does Simulations Plus, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Simulations Plus, Inc.?

Simulations Plus, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be April 9, 2026. The company currently has a trailing EPS of -3.20.

Company Profile

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through Software and Services segments. The company offers GastroPlus, which predicts absorption, biopharmaceutics, pharmacokinetics, and pharmacodynamics in humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, OBESITYsym, and Thales products. In addition, the company offers Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, it provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, the company offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Research Triangle Park, North Carolina.

Exchange Ticker
NCM (Australia) SLP
Historical Dividends
Year Total Dividends
2024 0.18 USD
2023 0.24 USD
2022 0.24 USD
2021 0.24 USD
2020 0.24 USD
2019 0.24 USD
2018 0.24 USD
2017 0.21 USD
2016 0.20 USD
2015 0.20 USD
2014 0.20 USD
2013 0.10 USD
2012 0.34 USD

Yearly aggregated dividends

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
Aug. 14, 2006 2.000000
Oct. 2, 2007 2.000000
Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion